Author

C. Schuelein-Voelk

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Assay:proteomics· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Prieto-Garcia· 4 shared M. E. Diefenbacher· 4 shared M. Reissland· 4 shared O. Hartmann· 4 shared C. Muench· 3 shared I. Dikic· 3 shared M. Rosenfeldt· 3 shared K. Klann· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. Prieto-Garcia

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Direct RNA-binding by MYCN mediates feedback from RNA processing to transcription control

D. Papadopoulos, S. A. Ha, D. Fleischhauer, L. Uhl, K. Schneider, I. Mikicic, T. J. Russell, A. Brem, O. R. Valanju, P. Gallant, C. Schuelein-Voelk, H. M. Maric, P. Beli, G. Buechel, S. M. Vos, M. Eilers

This study shows MYCN binds RNA and regulates transcript turnover, with its RNA-binding activity affecting transcription control through competition with DNA-binding.

bioRxiv · Aug 16, 2023 · PreprintCancer Biology

Stabilisation of β-Catenin-WNT signalling by USP10 in APC-truncated colorectal cancer drives cancer stemness and enables super-competitor signalling

M. Reissland, O. Hartmann, S. Tauch, C. Prieto-Garcia, C. Schulte, D. Solvie, S. Loebbert, A. C. Jacomin, M. Pesic, J. M. Bugter, C. Schuelein-Voelk, C. Fuss, N. Pahor, C. Ade, V. Buck, , M. E. Diefenbacher

This study identifies USP10 as a deubiquitylase that stabilizes β-Catenin in APC-truncated colorectal cancer, enhancing WNT signaling and cancer stemness.

bioRxiv · Feb 10, 2023 · PreprintCancer Biology

USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.

C. Prieto-Garcia, O. Hartmann, M. Reissland, F. Braun, S. Bozkurt, C. T. Fuss, C. Schuelein-Voelk, A. Buchberger, M. A. Calzado, M. T. Rosenfeldt, I. Dikic, C. Muench, M. E. Diefenbacher

This study shows USP28 promotes lung cancer by stabilizing oncogenes and its inhibition enhances therapy for EGFR, BRAF, and PI3K mutant tumors.

bioRxiv · Sep 6, 2021Cancer Biology

PTEN mutant NSCLC require ATM to suppress pro-apoptotic signalling and evade radiotherapy

T. Fischer, O. Hartmann, M. Reissland, C. Prieto-Garcia, K. Klann, C. Schuelein-Voelk, B. Polat, E. Gebhard-Hartmann, M. Rosenfeldt, C. Muench, M. Flentje, M. E. Diefenbacher

This study shows PTEN-deficient NSCLC cells rely on ATM to repair radiation damage and resist therapy, and ATM inhibition synergizes with radiation in these models.

bioRxiv · Jul 24, 2021 · PreprintCancer Biology

Inhibition of USP28 overcomes Cisplatin-Resistance of Squamous Tumors by Suppression of the Fanconi Anemia Pathway.

C. Prieto-Garcia, O. Hartmann, M. Reissland, T. Fischer, C. R. Maier, M. Rosenfeldt, C. Schuelein-Voelk, K. Klann, R. Kalb, I. Dikic, C. Muench, M. E. Diefenbacher

This study identifies USP28 inhibition as a strategy to overcome cisplatin resistance in squamous cell carcinomas by suppressing the Fanconi Anemia DNA repair pathway.

bioRxiv · Sep 10, 2020Cancer Biology